Bayer Cropscience India Limited

As of June 30, 2026, Bayer Cropscience India Limited carries a market capitalization of 186.35B, placing it among publicly traded companies globally. Its enterprise value stands at 186.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bayer Cropscience India Limited's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Bayer Cropscience India Limited has 44.94M shares outstanding.

As of June 30, 2026, Bayer Cropscience India Limited trades at a trailing price-to-earnings ratio of 25.45.

As of June 30, 2026, Bayer Cropscience India Limited trades at an EV/EBITDA multiple of 20.87 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 24.01 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 186.35B versus a market cap of 186.35B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 15.64M in revenue per employee across its workforce of 3,577.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Bayer Cropscience India Limited recorded 1.90B in income tax expense. That works out to an effective tax rate of 20.58, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 9.22B, leaving 7.32B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Bayer Cropscience India Limited's stock has declined approximately 32.32% over the past 52 weeks. The 50-day moving average sits at 3,813.42, while the 200-day moving average is 4,298.97.

Over the twelve months ended June 30, 2026, Bayer Cropscience India Limited generated 55.95B in revenue and converted that into 7.32B in net income, yielding earnings per share of 162.90. EBITDA reached 8.93B, while operating income came in at 7.76B.

Over the twelve months ended June 30, 2026, Bayer Cropscience India Limited posted a gross margin of 42.03, reflecting its pricing power and cost economics. The operating margin of 13.87 and net profit margin of 13.08 provide insight into operational efficiency.

Bayer Cropscience India Limited's most recent stock split took place on November 24, 2003 with a 1:10 split ratio.